I agree 10000000% our AWESOME feature, is, potentially, to treat the condition totally, glucose control and any underlying consequences - also, look back at our initial Ph2 data, it was SAFE and it showed material efficiency - but remember, safety was what the trial was primarily about, the dosage levels were relatively modest, but the outcomes evidenced clear dose dependency - exactly what Dr's like to see. No-doubt, over the last few months, the Prof and his team have been nutting out the strategy forward, toward a likely 2015 PhIII[1], which should see a few thousand tested and I'd expect to see some participants receive higher cell numbers too!
The above clearly has to factor in the results of the current "complications" trial, but I suspect both the FDA and MSB are going to want to "peddle to mettle" this one- if the safety holds up! Those T2D statistics out of the US would be scaring the hell out of 'em - another reason for their 7 FDA labs now working away on MSC's - clearly something BIG is rapidly building!
- Forums
- ASX - By Stock
- MSB
- T2D - Market Opportunity
T2D - Market Opportunity, page-3
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 24054 | 0.935 |
8 | 131583 | 0.930 |
4 | 65851 | 0.925 |
7 | 113334 | 0.920 |
9 | 97006 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 1100 | 1 |
0.950 | 19026 | 2 |
0.955 | 27000 | 2 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online